Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275238 | 0.85 | ALDH1A1 (0.42) | GAAALDH1A1NPC1SMN1; SMN2CHRM1 | |
| SCHEMBL12293104 | 0.84 | GAA (0.47) | GAAALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8313778 | 0.83 | GAA (0.42) | GAAALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17714542 | 0.82 | GAA (0.41) | GAAALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12928342 | 0.81 | GAA (0.49) | GAAALDH1A1SMN1; SMN2CHRM1L3MBTL1 | |
| SCHEMBL12347952 | 0.81 | ALDH1A1 (0.40) | GAAALDH1A1NPC1SMN1; SMN2CHRM1 | |
| SCHEMBL12898880 | 0.80 | GAA (0.44) | GAAALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12988938 | 0.80 | GAA (0.47) | GAAALDH1A1SMN1; SMN2CHRM1L3MBTL1 | |
| SCHEMBL23254247 | 0.79 | ALDH1A1 (0.42) | GAAALDH1A1NPC1SMN1; SMN2CHRM1 | |
| SCHEMBL18587995 | 0.79 | GAA (0.39) | GAAALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3344630-B1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-09 | — | — | EP | disclosed |
| US-20190315731-A1 | 6-(BUTA-1,3-DIYN-1-YL)BENZO[D]THIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2019-10-17 | — | — | US | disclosed |
| US-10314823-B2 | Substituted 1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-11 | — | — | US | disclosed |
| EP-3458453-A1 | 6-(BUTA-1,3-DIYN-1-YL)BENZO[D]THIAZOLE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2019-03-27 | — | — | EP | disclosed |
| US-20180250273-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-c]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | IDORSIA PHARMACEUTICALS LTD. (CH) | 2018-09-06 | — | — | US | disclosed |
| EP-3344630-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | Idorsia Pharmaceuticals Ltd (CH) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017198647-A1 | 6-(BUTA-1,3-DIYN-1-YL)BENZO[D]THIAZOLE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017037221-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315731-A1 | 6-(BUTA-1,3-DIYN-1-YL)BENZO[D]THIAZOLE DERIVATIVES | TMBIM6, BTN3A1, BET1 | GAA 1950/4885ALDH1A1 40/4885NPC1 790/4885 |
| US-10314823-B2 | Substituted 1,2-dihydro-3H-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds | MRPL21, MRM1, MT-CO1 | GAA 2285/4885ALDH1A1 103/4885NPC1 2629/4885 |
| US-20180250273-A1 | SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-c]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS | MRPL21, MRM1, MT-CO1 | GAA 2285/4885ALDH1A1 103/4885NPC1 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.